Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia

被引：53
作者：
Roy, L [1 ]
Guilhot, J [1 ]
Martineau, G [1 ]
Larchée, R [1 ]
Guilhot, F [1 ]
机构：
[1] CHU La Miletrie, Dept Oncol Hematol & Cell Therapie, Clin Res Ctr, F-86021 Poitiers, France
来源：
LEUKEMIA | 2005年 / 19卷 / 09期
关键词：
D O I：
10.1038/sj.leu.2403874
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1689 / 1692
页数：5
相关论文
共 13 条
  • [1] Solid cancers after bone marrow transplantation
    Bhatia, S
    Louie, AD
    Bhatia, R
    O'Donnell, MR
    Fung, H
    Kashyap, A
    Krishnan, A
    Molina, A
    Nademanee, A
    Niland, JC
    Parker, PA
    Snyder, DS
    Spielberger, R
    Stein, A
    Forman, SJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 464 - 471
  • [2] To the editor: Discontinuation of imatinib therapy after achieving a molecular response
    Cortes, J
    O'Brien, S
    Kantarjian, H
    [J]. BLOOD, 2004, 104 (07) : 2204 - 2205
  • [3] The development of imatinib as a therapeutic agent for chronic myeloid leukemia
    Deininger, M
    Buchdunger, E
    Druker, BJ
    [J]. BLOOD, 2005, 105 (07) : 2640 - 2653
  • [4] Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia
    Guilhot, F
    Chastang, C
    Michallet, M
    Guerci, A
    Harousseau, JL
    Maloisel, F
    Bouabdallah, R
    Guyotat, D
    Cheron, N
    Nicolini, F
    Abgrall, JF
    Tanzer, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) : 223 - 229
  • [5] Sustained durability of responses plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy: Update from the IRIS study.
    Guilhot, F
    [J]. BLOOD, 2004, 104 (11) : 10A - 10A
  • [6] Indications for imatinib mesylate therapy and clinical management
    Guilhot, F
    [J]. ONCOLOGIST, 2004, 9 (03) : 271 - 281
  • [7] A MULTICENTRIC RANDOMIZED STUDY OF ALPHA-2B INTERFERON (IFN) AND HYDROXYUREA (HU) WITH OR WITHOUT CYTOSINE-ARABINOSIDE (ARA-C) IN PREVIOUSLY UNTREATED PATIENTS WITH PH+ CHRONIC MYELOCYTIC-LEUKEMIA (CML) - PRELIMINARY CYTOGENETIC RESULTS
    GUILHOT, F
    ABGRALL, JF
    HAROUSSEAU, JL
    BAUTERS, F
    BRICE, P
    DINE, G
    TILLY, H
    IFRAH, N
    CASSASUS, P
    ROCHANT, H
    CHRISTIAN, B
    GUERCI, A
    LAMAGNERE, JP
    LEPRISE, PY
    DUCLOS, B
    TANZER, J
    [J]. LEUKEMIA & LYMPHOMA, 1993, 11 : 181 - 183
  • [8] Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II):: prolongation of survival by the combination of interferon α and hydroxyurea
    Hehlmann, R
    Berger, U
    Pfirrmann, M
    Hochhaus, A
    Metzgeroth, G
    Maywald, O
    Hasford, J
    Reiter, A
    Hossfeld, DK
    Kolb, HJ
    Löffler, H
    Pralle, H
    Queisser, W
    Griesshammer, M
    Nerl, C
    Kuse, R
    Tobler, A
    Eimermacher, H
    Tichelli, A
    Aul, C
    Wilhelm, M
    Fischer, JT
    Perker, M
    Scheid, C
    Schenk, M
    Weiss, J
    Meier, CR
    Kremers, S
    Labedzki, L
    Schmeiser, T
    Lohrmann, HP
    Heimpel, H
    [J]. LEUKEMIA, 2003, 17 (08) : 1529 - 1537
  • [9] Malignant neoplasms in long-term survivors of bone marrow transplantation
    Kolb, HJ
    Socié, G
    Duell, T
    Van Lint, MT
    Tichelli, A
    Apperley, JF
    Nekolla, E
    Ljungman, P
    Jacobsen, N
    van Weel, M
    Wick, R
    Weiss, M
    Prentice, HG
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (10) : 738 - +
  • [10] Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phase
    Maloisel, F
    Guerci, A
    Guyotat, D
    Ifrah, N
    Michallet, M
    Reiffers, J
    Tertain, G
    Blanc, M
    Bauduer, F
    Brière, J
    Abgrall, JF
    Pegourie-Bandelier, B
    Solary, E
    Cambier, N
    Coso, D
    Vilque, JP
    Delain, M
    Harousseau, JL
    Rousselot, P
    Belhadj, K
    Morice, P
    Attal, J
    Chabin, M
    Chastang, C
    Guilhot, J
    Guilhot, F
    [J]. LEUKEMIA, 2002, 16 (04) : 573 - 580
12